Dana-Farber’s Breast Oncology Center· @DFCI_BreastOnc · X·· 17 hours agoScore70
Body
Dr. Erica Mayer (@elmayermd) at the #ESMO26 HR+ breast cancer poster session showcasing a recent expert consensus on the management of ribociclib-associated liver-related adverse events in HR+/HER2− #BreastCancer.
59 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA25matched by Proffered paper 1: Breast cancer, early and advanced stage
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.orgSource: Dana-Farber’s Breast Oncology Center · x.com